Santhera drug is investigated in DMD

Santhera Pharmaceuticals is often a Swiss specialty pharmaceutical company focusing for the progress and marketing of revolutionary pharmaceutical products to the treatment of orphan neuromuscular diseases. Santhera presently has three compounds in seven clinical-stage progress programs.

Santhera’s vision is to turn out to be a major specialty pharmaceutical company providing therapies for any number of indications on this area of high unmet medical need which includes a great deal of orphan indications without any existing therapy.

Santhera’s very first product, Catena® has received a marketing approval from health Canada to deal with Friedreich’s Ataxia. in a current clinical study, Catena® has long been shown to improve the vision of patients struggling with Leber’s Hereditary Optic Neuropathy (LHON). Regulatory submissions as potenially very first treatment of the indication are planned in the very first half of 2011.

The medication is presently investigated in Duchenne Muscular Dystrophy (Phase III),

MELAS syndrome (Phase IIa) and major Progressive multiple Sclerosis (Phase II). Santhera has partnered European commercialization rights for Catena®/Sovrima® in Friedreich’s Ataxia and Duchenne Muscular Dystrophy to Takeda.

Santhera’s second main program is fipamezole to the treatment of Dyskinesia in Parkinson’s Disease. In 2009, a period IIb confirmed the efficacy of fipamezole in cutting down levodopa-induced dyskinesia in Parkinson’s patients. progress and commercialization rights outside North America and Japan are partnered to Ipsen.

Nonclinical operate for omigapil, the third compound, was lately completed for clinical progress in Congenital Muscular Dystrophies.

Tagged on: ,

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>